[96a5a0]: / output / allTrials / identified / NCT01411072_identified.json

Download this file

832 lines (832 with data), 39.9 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
{
"info": {
"nct_id": "NCT01411072",
"official_title": "Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer",
"inclusion_criteria": "* Histologically documented pancreatic adenocarcinoma not previously treated with systemic therapy.\n* Complete macroscopic and microscopic (R0) resection for ductal adenocarcinoma of the pancreas with no evidence of malignant ascites, peritoneal metastases or distant metastases. Lack of recurrent and/metastatic disease must be confirmed radiologically with CT chest, abdomen, and pelvis prior to enrolment.\n* Adequate tissue available for IHC testing of hENT1. Histological/cytological confirmation of tissue to ensure sufficient material is available for hENT1 analysis by the Cross Cancer Institute (CCI) is required. Paraffin block sufficient for preparing ≥ 6 unstained slides for central storage and testing if required by oncologist.\n* ECOG performance status of 0 - 2. (Appendix B)\n* Age ≥ 18 years\n* Life expectancy of at least 6 months based on discretion of treating\n* Adequate hematologic function defined by the following laboratory parameters: Hemoglobin > 100, Platelet count > 100 and Absolute granulocyte count > 1.5.\n* Adequate hepatic and renal function defined by the following laboratory parameters: AST and ALT ≤ 2.5 X upper limit of institutional normal, bilirubin ≤ upper limit of institutional normal, and calculated creatinine clearance of ≥ 50 mL/min using the Cockcroft-Gault formula, if just below 50 mL/min based on this formula then GFR ≥ 50 mL/min as determined.\n* Patients may have received prior curative radiotherapy for a different malignancy (unless radiation was curative therapy to ≥ 25% of bone marrow stores) and patients must have recovered from the toxic effects of this treatment.\n* Patients must be started on protocol ≤ 10 weeks from the date of curative surgical resection, and patients must have recovered from the toxic effects of surgery.\n* Patients must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Patients who have received prior chemotherapy or radiation delivered as parts of initial curative therapy for pancreas cancer (i.e. neoadjuvant or adjuvant chemotherapy administered alone and/or concurrently delivered with radiation and/or surgery) are not permitted. Metastatic patients are not permitted.\n* Prior treatment for a different malignancy with > 6 cycles of traditional alkylating agent-based chemotherapy, > 2 cycles of carboplatin-based chemotherapy, or concurrent treatment with other experimental drugs or anti-cancer therapy.\n* Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, short gut syndrome, or history of bowel obstruction due to peritoneal metastases.\n* Previous or concurrent malignancies, excluding curatively treated in situ carcinoma of the cervix or non-melanoma skin cancer, unless at least 5 years have elapsed since last treatment and the patient is considered cured.\n* Any serious medical condition within 6 months prior to study entry such as myocardial infarction, uncontrolled congestive heart failure, unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, cerebrovascular diseases, uncontrolled hypertension, uncontrolled diabetes, uncontrolled psychiatric disorder, serious infection, active peptic ulcer disease, or other medical condition that.\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency.\n* Pregnant or lactating women; women of child bearing potential must have a negative serum pregnancy test within 7 days of trial registration. Women or men of child bearing potential must use effective contraception (defined by the treating physician) which must be documented in study CRFs.\n* Any other reason the investigator considers the patient should not participate in the study",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Histologically documented pancreatic adenocarcinoma not previously treated with systemic therapy.",
"criterions": [
{
"exact_snippets": "Histologically documented pancreatic adenocarcinoma",
"criterion": "pancreatic adenocarcinoma",
"requirements": [
{
"requirement_type": "documentation",
"expected_value": "histologically"
}
]
},
{
"exact_snippets": "not previously treated with systemic therapy",
"criterion": "systemic therapy",
"requirements": [
{
"requirement_type": "treatment history",
"expected_value": false
}
]
}
]
},
{
"line": "* Complete macroscopic and microscopic (R0) resection for ductal adenocarcinoma of the pancreas with no evidence of malignant ascites, peritoneal metastases or distant metastases. Lack of recurrent and/metastatic disease must be confirmed radiologically with CT chest, abdomen, and pelvis prior to enrolment.",
"criterions": [
{
"exact_snippets": "Complete macroscopic and microscopic (R0) resection for ductal adenocarcinoma of the pancreas",
"criterion": "resection for ductal adenocarcinoma of the pancreas",
"requirements": [
{
"requirement_type": "completeness",
"expected_value": "complete"
},
{
"requirement_type": "type",
"expected_value": [
"macroscopic",
"microscopic (R0)"
]
}
]
},
{
"exact_snippets": "no evidence of malignant ascites",
"criterion": "malignant ascites",
"requirements": [
{
"requirement_type": "evidence",
"expected_value": false
}
]
},
{
"exact_snippets": "no evidence of ... peritoneal metastases",
"criterion": "peritoneal metastases",
"requirements": [
{
"requirement_type": "evidence",
"expected_value": false
}
]
},
{
"exact_snippets": "no evidence of ... distant metastases",
"criterion": "distant metastases",
"requirements": [
{
"requirement_type": "evidence",
"expected_value": false
}
]
},
{
"exact_snippets": "Lack of recurrent and/metastatic disease must be confirmed radiologically with CT chest, abdomen, and pelvis",
"criterion": "recurrent and/or metastatic disease",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "radiologically with CT chest, abdomen, and pelvis"
}
]
}
]
},
{
"line": "* Adequate tissue available for IHC testing of hENT1. Histological/cytological confirmation of tissue to ensure sufficient material is available for hENT1 analysis by the Cross Cancer Institute (CCI) is required. Paraffin block sufficient for preparing ≥ 6 unstained slides for central storage and testing if required by oncologist.",
"criterions": [
{
"exact_snippets": "Adequate tissue available for IHC testing of hENT1",
"criterion": "tissue availability for IHC testing of hENT1",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
},
{
"exact_snippets": "Histological/cytological confirmation of tissue",
"criterion": "histological/cytological confirmation of tissue",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": true
}
]
},
{
"exact_snippets": "sufficient material is available for hENT1 analysis",
"criterion": "sufficient material for hENT1 analysis",
"requirements": [
{
"requirement_type": "availability",
"expected_value": true
}
]
},
{
"exact_snippets": "Paraffin block sufficient for preparing ≥ 6 unstained slides",
"criterion": "paraffin block for preparing unstained slides",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "unstained slides"
}
}
]
}
]
},
{
"line": "* ECOG performance status of 0 - 2. (Appendix B)",
"criterions": [
{
"exact_snippets": "ECOG performance status of 0 - 2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* Age ≥ 18 years",
"criterions": [
{
"exact_snippets": "Age ≥ 18 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Life expectancy of at least 6 months based on discretion of treating",
"criterions": [
{
"exact_snippets": "Life expectancy of at least 6 months",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "months"
}
}
]
}
]
},
{
"line": "* Adequate hematologic function defined by the following laboratory parameters: Hemoglobin > 100, Platelet count > 100 and Absolute granulocyte count > 1.5.",
"criterions": [
{
"exact_snippets": "Hemoglobin > 100",
"criterion": "hemoglobin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 100,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "Platelet count > 100",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 100,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "Absolute granulocyte count > 1.5",
"criterion": "absolute granulocyte count",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Adequate hepatic and renal function defined by the following laboratory parameters: AST and ALT ≤ 2.5 X upper limit of institutional normal, bilirubin ≤ upper limit of institutional normal, and calculated creatinine clearance of ≥ 50 mL/min using the Cockcroft-Gault formula, if just below 50 mL/min based on this formula then GFR ≥ 50 mL/min as determined.",
"criterions": [
{
"exact_snippets": "Adequate hepatic and renal function defined by the following laboratory parameters: AST and ALT ≤ 2.5 X upper limit of institutional normal",
"criterion": "AST and ALT levels",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "X upper limit of institutional normal"
}
}
]
},
{
"exact_snippets": "bilirubin ≤ upper limit of institutional normal",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "upper limit of institutional normal"
}
}
]
},
{
"exact_snippets": "calculated creatinine clearance of ≥ 50 mL/min using the Cockcroft-Gault formula",
"criterion": "creatinine clearance",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "mL/min"
}
}
]
},
{
"exact_snippets": "if just below 50 mL/min based on this formula then GFR ≥ 50 mL/min as determined",
"criterion": "GFR",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "mL/min"
}
}
]
}
]
},
{
"line": "* Patients may have received prior curative radiotherapy for a different malignancy (unless radiation was curative therapy to ≥ 25% of bone marrow stores) and patients must have recovered from the toxic effects of this treatment.",
"criterions": [
{
"exact_snippets": "Patients may have received prior curative radiotherapy for a different malignancy",
"criterion": "prior curative radiotherapy for a different malignancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "unless radiation was curative therapy to ≥ 25% of bone marrow stores",
"criterion": "radiation to bone marrow stores",
"requirements": [
{
"requirement_type": "coverage",
"expected_value": {
"operator": ">=",
"value": 25,
"unit": "%"
}
},
{
"requirement_type": "curative",
"expected_value": true
}
]
},
{
"exact_snippets": "patients must have recovered from the toxic effects of this treatment",
"criterion": "recovery from toxic effects of prior treatment",
"requirements": [
{
"requirement_type": "recovery",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients must be started on protocol ≤ 10 weeks from the date of curative surgical resection, and patients must have recovered from the toxic effects of surgery.",
"criterions": [
{
"exact_snippets": "Patients must be started on protocol ≤ 10 weeks from the date of curative surgical resection",
"criterion": "time from surgical resection to protocol start",
"requirements": [
{
"requirement_type": "time",
"expected_value": {
"operator": "<=",
"value": 10,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "patients must have recovered from the toxic effects of surgery",
"criterion": "recovery from toxic effects of surgery",
"requirements": [
{
"requirement_type": "recovery",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up.",
"criterions": [
{
"exact_snippets": "ability to read, understand, and sign an informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "ability",
"expected_value": [
"read",
"understand",
"sign"
]
}
]
},
{
"exact_snippets": "willing to comply with study treatment and follow-up",
"criterion": "compliance",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients who have received prior chemotherapy or radiation delivered as parts of initial curative therapy for pancreas cancer (i.e. neoadjuvant or adjuvant chemotherapy administered alone and/or concurrently delivered with radiation and/or surgery) are not permitted. Metastatic patients are not permitted.",
"criterions": [
{
"exact_snippets": "Patients who have received prior chemotherapy",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "prior ... radiation delivered as parts of initial curative therapy for pancreas cancer",
"criterion": "prior radiation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Metastatic patients are not permitted",
"criterion": "metastatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Prior treatment for a different malignancy with > 6 cycles of traditional alkylating agent-based chemotherapy, > 2 cycles of carboplatin-based chemotherapy, or concurrent treatment with other experimental drugs or anti-cancer therapy.",
"criterions": [
{
"exact_snippets": "Prior treatment for a different malignancy with > 6 cycles of traditional alkylating agent-based chemotherapy",
"criterion": "prior treatment with traditional alkylating agent-based chemotherapy",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 6,
"unit": "cycles"
}
}
]
},
{
"exact_snippets": "Prior treatment for a different malignancy with ... > 2 cycles of carboplatin-based chemotherapy",
"criterion": "prior treatment with carboplatin-based chemotherapy",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 2,
"unit": "cycles"
}
}
]
},
{
"exact_snippets": "Prior treatment for a different malignancy with ... concurrent treatment with other experimental drugs or anti-cancer therapy",
"criterion": "concurrent treatment with other experimental drugs or anti-cancer therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, short gut syndrome, or history of bowel obstruction due to peritoneal metastases.",
"criterions": [
{
"exact_snippets": "Lack of physical integrity of the upper gastrointestinal tract",
"criterion": "physical integrity of the upper gastrointestinal tract",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "malabsorption syndrome",
"criterion": "malabsorption syndrome",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "short gut syndrome",
"criterion": "short gut syndrome",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "history of bowel obstruction due to peritoneal metastases",
"criterion": "history of bowel obstruction due to peritoneal metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Previous or concurrent malignancies, excluding curatively treated in situ carcinoma of the cervix or non-melanoma skin cancer, unless at least 5 years have elapsed since last treatment and the patient is considered cured.",
"criterions": [
{
"exact_snippets": "Previous or concurrent malignancies",
"criterion": "malignancies",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "curatively treated in situ carcinoma of the cervix",
"criterion": "in situ carcinoma of the cervix",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "curatively treated"
}
]
},
{
"exact_snippets": "non-melanoma skin cancer",
"criterion": "non-melanoma skin cancer",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "curatively treated"
}
]
},
{
"exact_snippets": "unless at least 5 years have elapsed since last treatment and the patient is considered cured",
"criterion": "time since last treatment",
"requirements": [
{
"requirement_type": "time elapsed",
"expected_value": {
"operator": ">=",
"value": 5,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Any serious medical condition within 6 months prior to study entry such as myocardial infarction, uncontrolled congestive heart failure, unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, cerebrovascular diseases, uncontrolled hypertension, uncontrolled diabetes, uncontrolled psychiatric disorder, serious infection, active peptic ulcer disease, or other medical condition that.",
"criterions": [
{
"exact_snippets": "serious medical condition within 6 months prior to study entry",
"criterion": "serious medical condition",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": "within 6 months prior to study entry"
}
]
},
{
"exact_snippets": "myocardial infarction",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "uncontrolled congestive heart failure",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
},
{
"exact_snippets": "unstable angina",
"criterion": "angina",
"requirements": [
{
"requirement_type": "stability",
"expected_value": false
}
]
},
{
"exact_snippets": "active cardiomyopathy",
"criterion": "cardiomyopathy",
"requirements": [
{
"requirement_type": "activity",
"expected_value": true
}
]
},
{
"exact_snippets": "unstable ventricular arrhythmia",
"criterion": "ventricular arrhythmia",
"requirements": [
{
"requirement_type": "stability",
"expected_value": false
}
]
},
{
"exact_snippets": "cerebrovascular diseases",
"criterion": "cerebrovascular diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "uncontrolled hypertension",
"criterion": "hypertension",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
},
{
"exact_snippets": "uncontrolled diabetes",
"criterion": "diabetes",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
},
{
"exact_snippets": "uncontrolled psychiatric disorder",
"criterion": "psychiatric disorder",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
},
{
"exact_snippets": "serious infection",
"criterion": "serious infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "active peptic ulcer disease",
"criterion": "peptic ulcer disease",
"requirements": [
{
"requirement_type": "activity",
"expected_value": true
}
]
}
]
},
{
"line": "* Known dihydropyrimidine dehydrogenase (DPD) deficiency.",
"criterions": [
{
"exact_snippets": "Known dihydropyrimidine dehydrogenase (DPD) deficiency.",
"criterion": "dihydropyrimidine dehydrogenase (DPD) deficiency",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Pregnant or lactating women; women of child bearing potential must have a negative serum pregnancy test within 7 days of trial registration. Women or men of child bearing potential must use effective contraception (defined by the treating physician) which must be documented in study CRFs.",
"criterions": [
{
"exact_snippets": "Pregnant or lactating women",
"criterion": "pregnancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "not pregnant"
},
{
"requirement_type": "status",
"expected_value": "not lactating"
}
]
},
{
"exact_snippets": "women of child bearing potential must have a negative serum pregnancy test within 7 days of trial registration",
"criterion": "serum pregnancy test",
"requirements": [
{
"requirement_type": "result",
"expected_value": "negative"
},
{
"requirement_type": "timing",
"expected_value": "within 7 days of trial registration"
}
]
},
{
"exact_snippets": "Women or men of child bearing potential must use effective contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "status",
"expected_value": "effective contraception"
}
]
}
]
},
{
"line": "* Any other reason the investigator considers the patient should not participate in the study",
"criterions": [
{
"exact_snippets": "Any other reason the investigator considers the patient should not participate",
"criterion": "investigator's discretion",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": "reason to exclude"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}